0002149916 spac:NoRedemptionMember 2026-09-25 2026-09-25 0002149916 us-gaap:LoansMember ck0002149916:TCGXSponsorLLCMember 2026-09-25 2026-09-25 0002149916 spac:CommonSharesMember 2026-09-25 2026-09-25 0002149916 ck0002149916:InitialShareholdersMember 2026-09-25 2026-09-25 0002149916 ck0002149916:OurSponsorOrMembersMember 2026-09-25 2026-09-25 0002149916 spac:SpacOfficersAndDirectorsMember 2026-09-25 2026-09-25 0002149916 2026-09-25 2026-09-25 0002149916 spac:RedemptionAt75PercentOfMaximumMember 2026-09-25 2026-09-25 0002149916 spac:OverAllotmentOptionNotExercisedMember spac:RedemptionAt100PercentOfMaximumMember 2026-09-25 2026-09-25 0002149916 ck0002149916:PrivatePlacementSharesMember ck0002149916:TCGXSponsorLLCMember 2026-09-25 2026-09-25 0002149916 ck0002149916:PrivatePlacementSharesMember 2026-09-25 2026-09-25 0002149916 ck0002149916:UnderwritingCommissionsMember ck0002149916:TCGXSponsorLLCMember 2026-09-25 2026-09-25 0002149916 spac:RedemptionAt25PercentOfMaximumMember 2026-09-25 2026-09-25 0002149916 spac:RedemptionAt50PercentOfMaximumMember 2026-09-25 2026-09-25 0002149916 spac:CommonSharesMember ck0002149916:TCGXSponsorLLCMember 2026-09-25 2026-09-25 0002149916 spac:RedemptionAt100PercentOfMaximumMember 2026-09-25 2026-09-25 0002149916 dei:BusinessContactMember 2026-09-25 2026-09-25 0002149916 spac:OverAllotmentOptionNotExercisedMember spac:RedemptionAt75PercentOfMaximumMember 2026-09-25 2026-09-25 iso4217:USD shares shares iso4217:USD 10.00 10.00 0002149916 false KY S-1 TCGX Acquisition Corp. II 6770 98-1949103 245 Lytton Ave. Suite 350 Palo Alto CA 94301 650 924-9424 Dr. Chen Yu 245 Lytton Ave. Suite 350 Palo Alto CA 94301 650 924-9424 Non-accelerated Filer true true false If we are unable to complete our initial business combination within 24 months from the closing of this offering, or such other time period in which we must complete an initial business combination pursuant to an amendment to our amended and restated memorandum and articles of association, which we refer to as the completion window, we will redeem 100% of the public shares at a per share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding public shares, subject to applicable law and certain conditions as further described herein. We may seek shareholder approval to amend our amended and restated memorandum and articles of association to extend the date by which we must consummate our initial business combination. If we seek shareholder approval for an extension, holders of our public shares will be offered an opportunity to redeem their shares upon approval of such extension, regardless of whether they abstain, vote in favor of or vote against such extension. P24M true We may seek shareholder approval to amend our amended and restated memorandum and articles of association to extend the date by which we must consummate our initial business combination. true true true The following table illustrates the difference between the public offering price and our net tangible book value per share, as adjusted to reflect various potential redemption levels that may occur in connection with the closing of our initial business combination, which we refer to as Adjusted NTBVPS, on a pro forma basis to give effect to this offering and the issuance of the private placement shares. Adjusted NTBVPS excludes the effect of the consummation of our initial business combination or any related transactions or expenses. See the section titled “Dilution” for more information. <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:9%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.74%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.84%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.84%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.84%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.5%;box-sizing:content-box;"></td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td colspan="17" style="border-top:0.5pt solid;padding-top:0.02in;padding-left:0in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">AS OF JULY 24, 2026</td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">OFFERING PRICE OF $10.00</td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td colspan="3" style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">25% OF MAXIMUM REDEMPTION</td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td colspan="3" style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">50% OF MAXIMUM REDEMPTION</td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td colspan="3" style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">75% OF MAXIMUM REDEMPTION</td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td colspan="3" style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">MAXIMUM REDEMPTION</td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">ADJUSTED NTBVPS</td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">ADJUSTED NTBVPS</td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">DIFFERENCE BETWEEN ADJUSTED NTBVPS AND OFFERING PRICE</td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">ADJUSTED NTBVPS</td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">DIFFERENCE BETWEEN ADJUSTED NTBVPS AND OFFERING PRICE</td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">ADJUSTED NTBVPS</td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">DIFFERENCE BETWEEN ADJUSTED NTBVPS AND OFFERING PRICE</td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">ADJUSTED NTBVPS</td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">DIFFERENCE BETWEEN ADJUSTED NTBVPS AND OFFERING PRICE</td> </tr> <tr style="height:7pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">$ 7.68</td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;"> </td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">$ 7.13</td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;"> </td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">$ 2.87</td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;"> </td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">$ 6.23</td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;"> </td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">$ 3.77</td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;"> </td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">$ 4.49</td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;"> </td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">$ 5.51</td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;"> </td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">$(0.17)</td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;"> </td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid;padding-right:0in;">$ 10.17</td> </tr> </table> 10 10 10 10 10 10 10 10 7.68 7.13 2.87 6.23 3.77 4.49 5.51 -0.17 10.17 true <div>Our Sponsor<div>Our sponsor, TCGX Sponsor II, LLC, is a Delaware limited liability company and was formed to invest in us. Although our sponsor is permitted to undertake any activities permitted under the Delaware Limited Liability Company Act and other applicable law, our sponsor’s business is focused on investing in our company. The manager of our sponsor is Chen Yu, M.D., M.B.A., our Chief Executive Officer and a director. Dr. Yu controls the management of our sponsor, including the exercise of voting and investment discretion over the securities of our company held by our sponsor. As of the date of this prospectus, Fund III owns 100% of the economic rights attributable to the founder shares and private placement shares held by our sponsor.</div></div><div>The following table sets forth the payments to be received by our sponsor and its affiliates from us prior to or in connection with the completion of our initial business combination and the securities issued and to be issued by us to our sponsor or its affiliates: <div> <table style="border-spacing:0;table-layout:auto;width:auto;border-collapse:separate;margin-right:auto;"> <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;"> <td style="width:1.0625in;box-sizing:content-box;"></td> <td style="width:0.0625in;box-sizing:content-box;"></td> <td style="width:3.75in;box-sizing:content-box;"></td> <td style="width:0.051388888888888894in;box-sizing:content-box;"></td> <td style="width:1.323611111111111in;box-sizing:content-box;"></td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;">ENTITY</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;">AMOUNT OF COMPENSATION TO BE RECEIVED OR SECURITIES ISSUED OR TO BE ISSUED</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;">CONSIDERATION PAID OR TO BE PAID</td> </tr> <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">TCGX Sponsor II, LLC</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">2,500,000 Class B ordinary shares, representing 20% of our issued and outstanding ordinary shares immediately following the completion of this offering (excluding the private placement shares). After taking into account the private placement shares to be issued to the sponsor, our sponsor will own an aggregate of 2,860,000 ordinary shares, or 22.1% of our issued and outstanding ordinary shares immediately following the completion of this offering. If we increase or decrease the size of this offering, we will effect a share capitalization or share repurchase or redemption or other appropriate mechanism, as applicable, with respect to our Class B ordinary shares immediately prior to the consummation of the offering in such amount as to maintain the ownership of founder shares by our initial shareholders at 20% of our issued and outstanding ordinary shares upon the consummation of this offering (excluding the private placement shares). The Class B ordinary shares will automatically convert into Class A ordinary shares immediately prior to, or concurrently with or immediately following the consummation of our business combination or at any time prior thereto at the option of the holder on a one-for-one basis subject to adjustment for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like, and subject to further adjustment as provided herein. In the case that additional Class A ordinary shares or equity-linked securities are issued or deemed issued in connection with our initial business combination, the number of Class A ordinary shares issuable upon conversion of all founder shares will equal, in the aggregate, 20% of the total number of Class A ordinary shares outstanding after such conversion (excluding the private placement shares and forward purchase shares, and after giving effect to any redemptions of Class A ordinary shares by public shareholders), including the total number of Class A ordinary shares issued, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the company in connection with or in relation to the consummation of the initial business combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, or to be issued, to any seller in the initial business combination and any private placement shares issued to our sponsor, officers or directors upon conversion of working capital loans; provided that such conversion of founder shares will never occur on a less than one-for-one basis. As a result of such anti-dilution adjustments, the founder shares held by our sponsor may convert into Class A ordinary shares on a greater than one-for-one basis, which may result in material dilution from your purchase of our Class A ordinary shares.</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">$25,000 (or approximately $0.01 per share)</td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">TCGX Sponsor II, LLC</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">450,000 private placement shares</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">$4,500,000 ($10.00 per share)</td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">TCGX Sponsor II, LLC, an affiliate thereof, or our officers and directors</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Repayment in cash or up to $3,000,000 in private placement shares of the post-business combination entity at a price of $10.00 per share at the option of the lender</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Loans to finance transaction costs in connection with an intended initial business combination</td> </tr> </table></div></div><div> <table style="border-spacing:0;table-layout:auto;width:auto;border-collapse:separate;margin-right:auto;"> <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;"> <td style="width:1.0625in;box-sizing:content-box;"></td> <td style="width:0.0625in;box-sizing:content-box;"></td> <td style="width:3.75in;box-sizing:content-box;"></td> <td style="width:0.051388888888888894in;box-sizing:content-box;"></td> <td style="width:1.323611111111111in;box-sizing:content-box;"></td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><div>ENTITY</div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><div> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><div>AMOUNT OF COMPENSATION TO BE RECEIVED OR SECURITIES ISSUED OR TO BE ISSUED</div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><div> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><div>CONSIDERATION PAID OR TO BE PAID</div></td> </tr> <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><div> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><div> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><div> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><div> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><div> </div></td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div>TCGX Sponsor II, LLC</div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div>Repayment in cash</div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div>Up to $300,000 under an unsecured, non-interest bearing promissory note for offering-related and organizational expenses. This loan is due at the earlier of December 31, 2027 or the closing of this offering and is anticipated to be repaid upon completion of this offering out of the $1,000,000 of offering proceeds that has been allocated for the payment of offering expenses other than underwriting commissions</div></td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div>TCGX Sponsor II, LLC Independent Directors</div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div>Anti-dilution protection upon conversion into Class A ordinary shares at a greater than one-to-one ratio</div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div>Issuance of the Class A ordinary shares issuable in connection with the conversion of the founder shares on a greater than one-to-one basis upon conversion</div></td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div>TCGX Sponsor II, LLC, our officers or directors, or affiliates thereof</div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div>Repayment in cash</div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div style="font-size:7.5pt;font-family:'TradeGothic LT',sans-serif;"> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div>Any out-of-pocket expenses related to identifying, investigating, negotiating and completing an initial business combination</div></td> </tr> </table></div><div> </div>Because our sponsor acquired the founder shares at a nominal price, our public shareholders will incur an immediate and material dilution upon the closing of this offering. See the sections titled “Dilution” and “Risk Factors—The nominal purchase price paid by our sponsor for the founder shares may significantly dilute the implied value of your public shares in the event we consummate an initial business combination, and our sponsor is likely to make a substantial profit on its investment in us in the event we consummate an initial business combination, even if the business combination causes the trading price of our ordinary shares to materially decline.”Pursuant to a letter agreement to be entered with us, we have agreed not to enter into a definitive agreement regarding an initial business combination without the prior consent of our sponsor. Further, pursuant to such letter agreement, each of our sponsor, officers and directors has agreed to restrictions on its ability to transfer, assign, or sell the founder shares and private placement shares, as summarized in the table below. Our letter agreement with our sponsor, officers and directors, which contains the below provisions relating to transfer restrictions of our founder shares and private placement shares, may be amended without shareholder approval. Such transfer restrictions have been amended in connection with business combinations for certain other special purpose acquisition companies. While we do not expect our board to approve any amendment to the letter agreement prior to our initial business combination, it may be possible that our board, in exercising its business judgment and subject to its fiduciary duties, chooses to approve one or more amendments to the letter agreement. <table style="border-spacing:0;table-layout:auto;width:auto;border-collapse:separate;margin-right:auto;"> <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;"> <td style="width:1.3131944444444443in;box-sizing:content-box;"></td> <td style="width:0.0625in;box-sizing:content-box;"></td> <td style="width:1.5625in;box-sizing:content-box;"></td> <td style="width:0.0625in;box-sizing:content-box;"></td> <td style="width:1.3125in;box-sizing:content-box;"></td> <td style="width:0.06527777777777778in;box-sizing:content-box;"></td> <td style="width:1.8715277777777777in;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;">SUBJECT SECURITIES</td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;">EXPIRATION DATE</td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;">PERSONS SUBJECT TO RESTRICTIONS</td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;">EXCEPTIONS TO TRANSFER RESTRICTIONS</td> </tr> <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Founder Shares</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div>The founder shares are not transferable or saleable until one year after the completion of our initial business combination or earlier if the last sale price of our Class A ordinary shares equals or exceeds $12.00 for any 20 trading days within any 30-trading day period commencing at least 180 days after the completion of our initial business combination.</div></td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">TCGX Sponsor II, LLC <div>Independent Directors</div></td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div>Transfers are permitted (a) to our officers or directors, any affiliate or family member of any of our officers or directors, any members or partners of our sponsor or their affiliates, any affiliates of our sponsor, or any employees of such affiliates, (b) in the case of an individual, as a gift to such person’s immediate family or to a trust, the beneficiary of which is a member of such person’s immediate family, an affiliate of such person or to a charitable organization; (c) in the case of an individual, by virtue of laws of descent and distribution upon death of such person; (d) in the case of an individual, pursuant to a qualified domestic relations order; (e) by private sales or transfers made in connection with any forward purchase agreement or similar arrangement or in connection with the consummation of a business combination at prices no greater than the price at which the shares were originally purchased; (f) by virtue of the laws of the Cayman Islands or our Sponsor’s limited liability company agreement upon dissolution of our sponsor, (g) in the event of our liquidation prior to our consummation of our initial business combination; or (h) in the event that, subsequent to our consummation of an initial business combination, we complete a liquidation, merger, share exchange or other similar transaction which results in all of our shareholders having the right to exchange their Class A ordinary shares for cash, securities or other property; provided, however, that in the case of clauses (a) through (f) these permitted transferees must enter into a written agreement agreeing to be bound by these transfer restrictions and the other restrictions contained in the letter agreements.</div></td> </tr> <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Private Placement Shares</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div>The private placement shares are not transferable or saleable until 30 days after the completion of our initial business combination.</div></td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">TCGX Sponsor II, LLC</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div>Same as above.</div></td> </tr> </table> Our Sponsor<div>Our sponsor, TCGX Sponsor II, LLC, is a Delaware limited liability company and was formed to invest in us. Although our sponsor is permitted to undertake any activities permitted under the Delaware Limited Liability Company Act and other applicable law, our sponsor’s business is focused on investing in our company. The manager of our sponsor is Chen Yu, M.D., M.B.A., our Chief Executive Officer and a director. Dr. Yu controls the management of our sponsor, including the exercise of voting and investment discretion over the securities of our company held by our sponsor. As of the date of this prospectus, Fund III owns 100% of the economic rights attributable to the founder shares and private placement shares held by our sponsor.</div>The following table sets forth the payments to be received by our sponsor and its affiliates from us prior to or in connection with the completion of our initial business combination and the securities issued and to be issued by us to our sponsor or its affiliates: <div> <table style="border-spacing:0;table-layout:auto;width:auto;border-collapse:separate;margin-right:auto;"> <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;"> <td style="width:1.0625in;box-sizing:content-box;"></td> <td style="width:0.0625in;box-sizing:content-box;"></td> <td style="width:3.75in;box-sizing:content-box;"></td> <td style="width:0.051388888888888894in;box-sizing:content-box;"></td> <td style="width:1.323611111111111in;box-sizing:content-box;"></td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;">ENTITY</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;">AMOUNT OF COMPENSATION TO BE RECEIVED OR SECURITIES ISSUED OR TO BE ISSUED</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;">CONSIDERATION PAID OR TO BE PAID</td> </tr> <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">TCGX Sponsor II, LLC</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">2,500,000 Class B ordinary shares, representing 20% of our issued and outstanding ordinary shares immediately following the completion of this offering (excluding the private placement shares). After taking into account the private placement shares to be issued to the sponsor, our sponsor will own an aggregate of 2,860,000 ordinary shares, or 22.1% of our issued and outstanding ordinary shares immediately following the completion of this offering. If we increase or decrease the size of this offering, we will effect a share capitalization or share repurchase or redemption or other appropriate mechanism, as applicable, with respect to our Class B ordinary shares immediately prior to the consummation of the offering in such amount as to maintain the ownership of founder shares by our initial shareholders at 20% of our issued and outstanding ordinary shares upon the consummation of this offering (excluding the private placement shares). The Class B ordinary shares will automatically convert into Class A ordinary shares immediately prior to, or concurrently with or immediately following the consummation of our business combination or at any time prior thereto at the option of the holder on a one-for-one basis subject to adjustment for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like, and subject to further adjustment as provided herein. In the case that additional Class A ordinary shares or equity-linked securities are issued or deemed issued in connection with our initial business combination, the number of Class A ordinary shares issuable upon conversion of all founder shares will equal, in the aggregate, 20% of the total number of Class A ordinary shares outstanding after such conversion (excluding the private placement shares and forward purchase shares, and after giving effect to any redemptions of Class A ordinary shares by public shareholders), including the total number of Class A ordinary shares issued, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the company in connection with or in relation to the consummation of the initial business combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, or to be issued, to any seller in the initial business combination and any private placement shares issued to our sponsor, officers or directors upon conversion of working capital loans; provided that such conversion of founder shares will never occur on a less than one-for-one basis. As a result of such anti-dilution adjustments, the founder shares held by our sponsor may convert into Class A ordinary shares on a greater than one-for-one basis, which may result in material dilution from your purchase of our Class A ordinary shares.</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">$25,000 (or approximately $0.01 per share)</td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">TCGX Sponsor II, LLC</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">450,000 private placement shares</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">$4,500,000 ($10.00 per share)</td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">TCGX Sponsor II, LLC, an affiliate thereof, or our officers and directors</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Repayment in cash or up to $3,000,000 in private placement shares of the post-business combination entity at a price of $10.00 per share at the option of the lender</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Loans to finance transaction costs in connection with an intended initial business combination</td> </tr> </table></div> <table style="border-spacing:0;table-layout:auto;width:auto;border-collapse:separate;margin-right:auto;"> <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;"> <td style="width:1.0625in;box-sizing:content-box;"></td> <td style="width:0.0625in;box-sizing:content-box;"></td> <td style="width:3.75in;box-sizing:content-box;"></td> <td style="width:0.051388888888888894in;box-sizing:content-box;"></td> <td style="width:1.323611111111111in;box-sizing:content-box;"></td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><div>ENTITY</div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><div> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><div>AMOUNT OF COMPENSATION TO BE RECEIVED OR SECURITIES ISSUED OR TO BE ISSUED</div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><div> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><div>CONSIDERATION PAID OR TO BE PAID</div></td> </tr> <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><div> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><div> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><div> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><div> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><div> </div></td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div>TCGX Sponsor II, LLC</div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div>Repayment in cash</div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div>Up to $300,000 under an unsecured, non-interest bearing promissory note for offering-related and organizational expenses. This loan is due at the earlier of December 31, 2027 or the closing of this offering and is anticipated to be repaid upon completion of this offering out of the $1,000,000 of offering proceeds that has been allocated for the payment of offering expenses other than underwriting commissions</div></td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div>TCGX Sponsor II, LLC Independent Directors</div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div>Anti-dilution protection upon conversion into Class A ordinary shares at a greater than one-to-one ratio</div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div>Issuance of the Class A ordinary shares issuable in connection with the conversion of the founder shares on a greater than one-to-one basis upon conversion</div></td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div>TCGX Sponsor II, LLC, our officers or directors, or affiliates thereof</div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div>Repayment in cash</div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div style="font-size:7.5pt;font-family:'TradeGothic LT',sans-serif;"> </div></td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><div>Any out-of-pocket expenses related to identifying, investigating, negotiating and completing an initial business combination</div></td> </tr> </table> Sponsor Our sponsor, TCGX Sponsor II, LLC, is a Delaware limited liability company and was formed to invest in us. Although our sponsor is permitted to undertake any activities permitted under the Delaware Limited Liability Company Act and other applicable law, our sponsor’s business is focused on investing in our company. The manager of our sponsor is Chen Yu, M.D., M.B.A., our Chief Executive Officer and a director. Dr. Yu controls the management of our sponsor, including the exercise of voting and investment discretion over the securities of our company held by our sponsor. As of the date of this prospectus, Fund III owns 100% of the economic rights attributable to the founder shares and private placement shares held by our sponsor. Delaware limited liability company Limited Liability Company The manager of our sponsor is Chen Yu, M.D., M.B.A., our Chief Executive Officer and a director. Dr. Yu controls the management of our sponsor, including the exercise of voting and investment discretion over the securities of our company held by our sponsor. Chen Yu, M.D., M.B.A Chen Yu, M.D., M.B.A Chief Executive Officer and a director <table style="border-spacing:0;table-layout:auto;width:auto;border-collapse:separate;margin-right:auto;"> <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;"> <td style="width:1.0625in;box-sizing:content-box;"></td> <td style="width:0.0625in;box-sizing:content-box;"></td> <td style="width:3.75in;box-sizing:content-box;"></td> <td style="width:0.051388888888888894in;box-sizing:content-box;"></td> <td style="width:1.323611111111111in;box-sizing:content-box;"></td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;">ENTITY</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;">AMOUNT OF COMPENSATION TO BE RECEIVED OR SECURITIES ISSUED OR TO BE ISSUED</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;">CONSIDERATION PAID OR TO BE PAID</td> </tr> <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">TCGX Sponsor II, LLC</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">2,500,000 Class B ordinary shares, representing 20% of our issued and outstanding ordinary shares immediately following the completion of this offering (excluding the private placement shares). After taking into account the private placement shares to be issued to the sponsor, our sponsor will own an aggregate of 2,860,000 ordinary shares, or 22.1% of our issued and outstanding ordinary shares immediately following the completion of this offering. If we increase or decrease the size of this offering, we will effect a share capitalization or share repurchase or redemption or other appropriate mechanism, as applicable, with respect to our Class B ordinary shares immediately prior to the consummation of the offering in such amount as to maintain the ownership of founder shares by our initial shareholders at 20% of our issued and outstanding ordinary shares upon the consummation of this offering (excluding the private placement shares). The Class B ordinary shares will automatically convert into Class A ordinary shares immediately prior to, or concurrently with or immediately following the consummation of our business combination or at any time prior thereto at the option of the holder on a one-for-one basis subject to adjustment for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like, and subject to further adjustment as provided herein. In the case that additional Class A ordinary shares or equity-linked securities are issued or deemed issued in connection with our initial business combination, the number of Class A ordinary shares issuable upon conversion of all founder shares will equal, in the aggregate, 20% of the total number of Class A ordinary shares outstanding after such conversion (excluding the private placement shares and forward purchase shares, and after giving effect to any redemptions of Class A ordinary shares by public shareholders), including the total number of Class A ordinary shares issued, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the company in connection with or in relation to the consummation of the initial business combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, or to be issued, to any seller in the initial business combination and any private placement shares issued to our sponsor, officers or directors upon conversion of working capital loans; provided that such conversion of founder shares will never occur on a less than one-for-one basis. As a result of such anti-dilution adjustments, the founder shares held by our sponsor may convert into Class A ordinary shares on a greater than one-for-one basis, which may result in material dilution from your purchase of our Class A ordinary shares.</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">$25,000 (or approximately $0.01 per share)</td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">TCGX Sponsor II, LLC</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">450,000 private placement shares</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">$4,500,000 ($10.00 per share)</td> </tr> <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">TCGX Sponsor II, LLC, an affiliate thereof, or our officers and directors</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Repayment in cash or up to $3,000,000 in private placement shares of the post-business combination entity at a price of $10.00 per share at the option of the lender</td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Loans to finance transaction costs in connection with an intended initial business combination</td> </tr> </table>ENTITY AMOUNT OF COMPENSATION TO BE RECEIVED OR SECURITIES ISSUED OR TO BE ISSUED CONSIDERATION PAID OR TO BE PAID TCGX Sponsor II, LLC Repayment in cash Up to $300,000 under an unsecured, non-interest bearing promissory note for offering-related and organizational expenses. This loan is due at the earlier of December 31, 2027 or the closing of this offering and is anticipated to be repaid upon completion of this offering out of the $1,000,000 of offering proceeds that has been allocated for the payment of offering expenses other than underwriting commissionsTCGX Sponsor II, LLC Independent Directors Anti-dilution protection upon conversion into Class A ordinary shares at a greater than one-to-one ratio Issuance of the Class A ordinary shares issuable in connection with the conversion of the founder shares on a greater than one-to-one basis upon conversionTCGX Sponsor II, LLC, our officers or directors, or affiliates thereof Repayment in cash Any out-of-pocket expenses related to identifying, investigating, negotiating and completing an initial business combination 2500000 25000 450000 4500000 3000000 300000 The founder shares are not transferable or saleable until one year after the completion of our initial business combination or earlier if the last sale price of our Class A ordinary shares equals or exceeds $12.00 for any 20 trading days within any 30-trading day period commencing at least 180 days after the completion of our initial business combination. TCGX Sponsor II, LLC Independent Directors Transfers are permitted (a) to our officers or directors, any affiliate or family member of any of our officers or directors, any members or partners of our sponsor or their affiliates, any affiliates of our sponsor, or any employees of such affiliates, (b) in the case of an individual, as a gift to such person’s immediate family or to a trust, the beneficiary of which is a member of such person’s immediate family, an affiliate of such person or to a charitable organization; (c) in the case of an individual, by virtue of laws of descent and distribution upon death of such person; (d) in the case of an individual, pursuant to a qualified domestic relations order; (e) by private sales or transfers made in connection with any forward purchase agreement or similar arrangement or in connection with the consummation of a business combination at prices no greater than the price at which the shares were originally purchased; (f) by virtue of the laws of the Cayman Islands or our Sponsor’s limited liability company agreement upon dissolution of our sponsor, (g) in the event of our liquidation prior to our consummation of our initial business combination; or (h) in the event that, subsequent to our consummation of an initial business combination, we complete a liquidation, merger, share exchange or other similar transaction which results in all of our shareholders having the right to exchange their Class A ordinary shares for cash, securities or other property; provided, however, that in the case of clauses (a) through (f) these permitted transferees must enter into a written agreement agreeing to be bound by these transfer restrictions and the other restrictions contained in the letter agreements. The private placement shares are not transferable or saleable until 30 days after the completion of our initial business combination. TCGX Sponsor II, LLC Same as above. Redemption of public shares and distribution and liquidation if no initial business combination: Our amended and restated memorandum and articles of association provide that we will have only the completion window to complete our initial business combination. If we are unable to complete our initial business combination within the completion window, we will as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding public shares, which redemption will constitute full and complete payment for the public shares and completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation or other distributions, if any), subject, in each case to our obligations under Cayman Islands law to provide for claims of creditors and in all cases subject to the other requirements of applicable law.Our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have waived their rights to liquidating distributions from the trust account with respect to any founder shares and private placement shares held by them if we fail to complete our initial business combination within the completion window, although they will be entitled to liquidating distributions from assets outside the trust account. However, if they acquire public shares in or after this offering, they will be entitled to liquidating distributions from the trust account with respect to such public shares if we fail to complete our initial business combination within the completion window. The underwriters have agreed to waive their rights to their deferred underwriting commission held in the trust account in the event we do not complete our initial business combination within the completion window and, in such event, such amounts will be included with the funds held in the trust account that will be available to fund the redemption of our public shares.Our sponsor, officers and directors have agreed, pursuant to a letter agreement, that they will not propose any amendment to our amended and restated memorandum and articles of association (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination within the completion window or (B) with respect to any other material provisions relating to shareholders’ rights or pre-initial business combination activity, unless we provide our public shareholders with the opportunity to redeem their Class A ordinary shares upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding public shares, subject to the limitations and on the conditions described above under “Limitations on redemptions.” For example, our board of directors may propose such an amendment if it determines that additional time is necessary to complete our initial business combination. In such event, we will conduct a proxy solicitation and distribute proxy materials pursuant to Regulation 14A of the Exchange Act seeking shareholder approval of such proposal, and in connection therewith, provide our public shareholders with the redemption rights described above upon shareholder approval of such amendment.Redemption rights for public shareholders upon amendment of our amended and restated memorandum and articles of association: If we seek to amend our amended and restated memorandum and articles of association (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination within the completion window or (B) with respect to any other material provisions relating to shareholders’ rights or pre-initial business combination activity, we will provide our public shareholders with the opportunity to redeem all or a portion of their Class A ordinary shares upon the approval of such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding public shares, subject to the limitations and on the conditions described herein. Payments to insiders: Prior to or in connection with our initial business combination, we expect to make certain payments and reimbursements to our sponsor, officers or directors, or our or their affiliates, including but not limited to the following, which, if made prior to our initial business combination will be made from funds held outside the trust account:<div class="item-list-element-wrapper" style="tab-size:32px;display:flex;font-size:9.5pt;margin-top:9pt;justify-content:flex-start;font-family:'TradeGothic LT',sans-serif;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;">▪<div style="display:inline;">Repayment of up to $300,000 in loans made to us by our sponsor to cover offering-related and organizational expenses;</div></div><div class="item-list-element-wrapper" style="tab-size:32px;display:flex;font-size:9.5pt;margin-top:2pt;justify-content:flex-start;font-family:'TradeGothic LT',sans-serif;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;">▪<div style="display:inline;">Reimbursement for any out-of-pocket expenses related to identifying, investigating, negotiating and completing an initial business combination;</div></div><div class="item-list-element-wrapper" style="tab-size:32px;display:flex;font-size:9.5pt;margin-top:2pt;justify-content:flex-start;font-family:'TradeGothic LT',sans-serif;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;">▪<div style="display:inline;">Payments to any business development consultant or personnel we may engage or employ in connection with our search for and/ or consummation of our initial business combination; and</div></div><div class="item-list-element-wrapper" style="tab-size:32px;display:flex;font-size:9.5pt;margin-top:2pt;justify-content:flex-start;font-family:'TradeGothic LT',sans-serif;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;">▪<div style="display:inline;">Repayment of loans which may be made by our sponsor or an affiliate of our sponsor or certain of our officers and directors to finance transaction costs in connection with an intended initial business combination. Up to $3,000,000 of such loans may be convertible into private placement shares of the post-business combination entity at a price of $10.00 per share at the option of the lender. Such shares would be identical to the private placement shares. Except for the foregoing, the terms of such loans, if any, have not been determined and no written agreements exist with respect to such loans.</div></div> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:auto;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:1.5in;box-sizing:content-box;"></td> <td style="width:0.0625in;box-sizing:content-box;"></td> <td style="width:4.6875in;box-sizing:content-box;"></td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0.02in;padding-left:0in;vertical-align:top;padding-bottom:0.02in;padding-right:0in;">Audit committee:</td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:top;padding-bottom:0.02in;padding-right:0in;"> </td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:top;padding-bottom:0.02in;padding-right:0in;">We will establish and maintain an audit committee, which will be comprised entirely of independent directors as and when required by the rules of Nasdaq and Rule 10A of the Exchange Act. Among its responsibilities, the audit committee will review on a quarterly basis all payments that were made to our sponsor, officers or directors, and our or their affiliates and monitor compliance with the other terms relating to this offering. If any noncompliance is identified, then the audit committee will be charged with the responsibility to promptly take all action necessary to rectify such noncompliance or otherwise to cause compliance with the terms of this offering. For more information, see the section entitled “Management—Committees of the Board of Directors—Audit Committee.</td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0.02in;padding-left:0in;vertical-align:top;padding-bottom:0.02in;padding-right:0in;"><div>Conflicts of Interest:</div></td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:top;padding-bottom:0.02in;padding-right:0in;"> </td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:top;padding-bottom:0.02in;padding-right:0in;"><div>Each of our officers and directors has, and any of them in the future may have, additional fiduciary or contractual obligations to at least one other entity pursuant to which such officer or director is or will be required to present a business combination opportunity to such entity. Accordingly, if any of our officers or directors becomes aware of a business combination opportunity which is suitable for an entity to which he or she has then-current fiduciary or contractual obligations, he or she will honor his or her fiduciary or contractual obligations to present such business combination opportunity to such other entity, subject to their fiduciary duties under Cayman Islands law. In particular, TCGX incorporated TCGX Acquisition Corp., a blank check company, with acquisition objectives similar to ours, that is actively seeking a business combination target. Our executive officers and two of our directors also serve as executive officers and directors of TCGX Acquisition Corp. Responsibilities owed to TCGX Acquisition Corp. may present additional conflicts of interest in pursuing an acquisition target, which could materially affect our ability to complete our initial business combination. As a result, our sponsor, officers and directors could have conflicts of interest in determining whether to present business combination opportunities to us or to any other SPAC with which they may become involved, including TCGX Acquisition Corp. If Messrs. Chen and Skaling become aware of a business combination opportunity which is suitable for an entity to which he has then-current fiduciary or contractual obligations, then, they may be required to honor such fiduciary or contractual obligations to present such business combination opportunity to such entity. If TCGX Acquisition Corp. decides to pursue any such opportunity, we may be precluded from pursuing such opportunity. Furthermore, our founders and our directors and officers, TCGX, or its affiliates expect in the future to become affiliated with other public special purpose acquisition companies, similar to TCGX Acquisition Corp., that may have acquisition objectives that are similar to ours. To minimize potential conflicts of interest which may arise from multiple affiliations with SPACs sponsored by affiliates of TCGX, unless a business combination opportunity is expressly offered to us or to one of our directors or officers solely in his or her capacity as our director and/or officer and such opportunity is one we are permitted to undertake and would otherwise be reasonable for us to pursue, subject to their other legal obligations, we expect that our officers and directors who are also officers and/or directors of TCGX Acquisition Corp. or any other SPACs sponsored by affiliates of TCGX will present suitable target businesses to us and the other applicable SPACs based on which SPAC went public first and taking into account any other reasonable considerations (such as </div></td> </tr> </table> Reimbursement for any out-of-pocket expenses related to identifying, investigating, negotiating and completing an initial business combination Conflicts of Interest:Each of our officers and directors has, and any of them in the future may have, additional fiduciary or contractual obligations to at least one other entity pursuant to which such officer or director is or will be required to present a business combination opportunity to such entity. Accordingly, if any of our officers or directors becomes aware of a business combination opportunity which is suitable for an entity to which he or she has then-current fiduciary or contractual obligations, he or she will honor his or her fiduciary or contractual obligations to present such business combination opportunity to such other entity, subject to their fiduciary duties under Cayman Islands law. In particular, TCGX incorporated TCGX Acquisition Corp., a blank check company, with acquisition objectives similar to ours, that is actively seeking a business combination target. Our executive officers and two of our directors also serve as executive officers and directors of TCGX Acquisition Corp. Responsibilities owed to TCGX Acquisition Corp. may present additional conflicts of interest in pursuing an acquisition target, which could materially affect our ability to complete our initial business combination. As a result, our sponsor, officers and directors could have conflicts of interest in determining whether to present business combination opportunities to us or to any other SPAC with which they may become involved, including TCGX Acquisition Corp. If Messrs. Chen and Skaling become aware of a business combination opportunity which is suitable for an entity to which he has then-current fiduciary or contractual obligations, then, they may be required to honor such fiduciary or contractual obligations to present such business combination opportunity to such entity. If TCGX Acquisition Corp. decides to pursue any such opportunity, we may be precluded from pursuing such opportunity. Furthermore, our founders and our directors and officers, TCGX, or its affiliates expect in the future to become affiliated with other public special purpose acquisition companies, similar to TCGX Acquisition Corp., that may have acquisition objectives that are similar to ours. To minimize potential conflicts of interest which may arise from multiple affiliations with SPACs sponsored by affiliates of TCGX, unless a business combination opportunity is expressly offered to us or to one of our directors or officers solely in his or her capacity as our director and/or officer and such opportunity is one we are permitted to undertake and would otherwise be reasonable for us to pursue, subject to their other legal obligations, we expect that our officers and directors who are also officers and/or directors of TCGX Acquisition Corp. or any other SPACs sponsored by affiliates of TCGX will present suitable target businesses to us and the other applicable SPACs based on which SPAC went public first and taking into account any other reasonable considerations (such as <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:auto;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:1.5in;box-sizing:content-box;"></td> <td style="width:0.0625in;box-sizing:content-box;"></td> <td style="width:4.6875in;box-sizing:content-box;"></td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0.02in;padding-left:0in;vertical-align:top;padding-bottom:0.02in;padding-right:0in;"> </td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:top;padding-bottom:0.02in;padding-right:0in;"> </td> <td style="padding-top:0.02in;padding-left:0in;vertical-align:top;padding-bottom:0.02in;padding-right:0in;">whether an initial business combination with such target business can realistically be consummated in the time remaining for each such SPAC).Our executive officers and our directors may have interests that differ from you in connection with the business combination, including the fact that they may lose their entire investment in us if our initial business combination is not completed, except to the extent they receive liquidating distributions from assets outside the trust account, and accordingly, may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction.Additionally, the personal and financial interests of our directors and executive officers may influence their motivation in timely identifying and pursuing an initial business combination or completing our initial business combination. For example, our directors and executive officers may prioritize a prospective initial business combination with a shorter timeline to completion over another acquisition target which may be more difficult or time-intensive to consummate. Consequently, our directors’ and executive officers’ discretion in identifying and selecting a suitable target business may result in a conflict of interest when determining whether the terms, conditions and timing of a particular business combination are appropriate and in our shareholders’ best interest, which could negatively impact the timing for a business combination.In addition to the above, our officers and directors are not required to commit any specified amount of time to our affairs, and, accordingly, may have conflicts of interest in allocating management time among various business activities, including selecting a business combination target and monitoring the related due diligence.Additionally, our sponsor and executive officers and directors have agreed to waive their redemption rights with respect to their founder shares, private placement shares and any public shares held by them in connection with the consummation of our initial business combination. Further, our sponsor and executive officers and directors have agreed to waive their redemption rights with respect to any founder shares held by them if we are unable to complete our initial business combination within the completion window. With certain limited exceptions, the founder shares will not be transferable, assignable or salable by our sponsor or its permitted transferees until one year after the completion of our initial business combination or earlier if the last sale price of our Class A ordinary shares equals or exceeds $12.00 for any 20 trading days within any 30-trading day period commencing at least 180 days after the completion of our initial business combination.Affiliates of TCGX and members of our board of directors will directly or indirectly own our securities following this offering, and accordingly, they may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction because of their financial interest in completing an initial business combination within the completion window. Our sponsor paid a nominal aggregate purchase price of $25,000 for the founder shares, or approximately $0.01 per share. Accordingly, our management team, which owns interests in our sponsor, may be more willing to pursue a business combination with a riskier or less-established target business than would be the case if our sponsor had paid the same per share price for the founder shares as our public shareholders paid for their public shares.</td> </tr> </table> Each of our officers and directors has, and any of them in the future may have, additional fiduciary or contractual obligations to at least one other entity pursuant to which such officer or director is or will be required to present a business combination opportunity to such entity. Accordingly, if any of our officers or directors becomes aware of a business combination opportunity which is suitable for an entity to which he or she has then-current fiduciary or contractual obligations, he or she will honor his or her fiduciary or contractual obligations to present such business combination opportunity to such other entity, subject to their fiduciary duties under Cayman Islands law. our sponsor, officers and directors could have conflicts of interest in determining whether to present business combination opportunities to us or to any other SPAC with which they may become involved, including TCGX Acquisition Corp. If Messrs. Chen and Skaling become aware of a business combination opportunity which is suitable for an entity to which he has then-current fiduciary or contractual obligations, then, they may be required to honor such fiduciary or contractual obligations to present such business combination opportunity to such entity. If TCGX Acquisition Corp. decides to pursue any such opportunity, we may be precluded from pursuing such opportunity. <div class="item-list-element-wrapper" style="margin-left:0.25in;tab-size:32px;display:flex;font-size:10pt;margin-top:2pt;justify-content:flex-start;font-family:'TradeGothic LT',sans-serif;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.1246777353820767%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">▪<div style="display:inline;">If we seek shareholder approval of our initial business combination, our initial shareholders and management team have agreed to vote in favor of such initial business combination, regardless of how our public shareholders vote.</div></div> Moreover, we may need to obtain additional financing to complete our initial business combination, either because the transaction requires more cash than is available from the proceeds held in our trust account and from the proceeds of the sale of the forward purchase shares or because we become obligated to redeem a significant number of our public shares upon completion of the business combination, in which case we may issue additional securities or incur debt in connection with such business combination. If we raise additional funds through equity or convertible debt issuances, our public shareholders may suffer significant dilution, and those securities could have rights that rank senior to our public shares. If we raise additional funds through the incurrence of indebtedness, such indebtedness would have rights that are senior to our equity securities and could contain covenants that restrict our operations. See “Risk Factors—The ability of our public shareholders to exercise redemption rights with respect to a large number of our shares and the amount of the deferred underwriting compensation may not allow us to complete the most desirable business combination or optimize our capital structure, and may substantially dilute your investment in us.” Further, as described above, due to the Class B Anti-Dilution Adjustment, our public shareholders may incur material dilution. true There is no limitation on our ability to raise funds through the issuance of equity or equity-linked securities or through loans, advances or other indebtedness in connection with our initial business combination, including pursuant to forward purchase agreements or backstop agreements we may enter into following consummation of this offering. If we are unable to complete our initial business combination because we do not have sufficient funds available to us, we will be forced to liquidate the trust account. Redemption Rights for Public Shareholders in Connection with the Completion of Our Initial Business Combination We will provide our public shareholders with the opportunity to redeem all or a portion of their Class A ordinary shares in connection with the completion of our initial business combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account calculated as of two business days prior to the consummation of the initial business combination, including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding public shares, subject to the limitations and on the conditions described herein. The amount in the trust account is initially anticipated to be $10.00 per public share. The per share amount we will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions we will pay to the underwriters. Our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have agreed to waive their redemption rights with respect to their founder shares, private placement shares and any public shares they may acquire during or after this offering in connection with the completion of our initial business combination. true Below is a table summarizing the entities to which our officers and directors currently have fiduciary duties or contractual obligations: <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:27%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:20%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:24%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;">INDIVIDUAL</td> <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;">ENTITY</td> <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;">ENTITY’S BUSINESS</td> <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"> </td> <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;">AFFILIATION</td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Chen Yu, M.D., M.B.A.</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">TCG Crossover Fund III, LP</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Investment Firm</td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;">Co-Founder and Chief Investment Officer</td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Pathalys Pharma, Inc.</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Biopharmaceutical</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Director</td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Alkeus Pharmaceuticals, Inc.</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Biopharmaceutical</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Director</td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Aviceda Therapeutics</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Biotechnology</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Director</td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">ADARx Pharmaceuticals, Inc.</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Biotechnology</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Director</td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Corxel Pharmaceuticals Limited</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Biopharmaceutical</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Director</td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">TCGX Acquisition Corp.</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Special Purpose Acquisition Company</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Chief Executive Officer and Director</td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">TCGX Asia Life Sciences Partners I, Ltd.</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Investment Firm</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Director</td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">TCGX (Hong Kong) Limited</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Investment Firm</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Director</td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Craig Skaling</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">TCG Crossover Fund III, LP</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Investment Firm</td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;">Managing Director and Head of Private Equity</td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">TCGX Acquisition Corp.</td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;">Special Purpose Acquisition Company</td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;">Chief Financial Officer and Director</td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;">TCGX Asia Life Sciences Partners I, Ltd.</td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;">Investment Firm</td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;">Director</td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;">TCGX (Hong Kong) Limited</td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;">Investment Firm</td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;">Director</td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Joshua Cohen</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Amylyx Pharmaceuticals, Inc.</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Biopharmaceutical</td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;">Co-Founder, Co-Chief Executive Officer and Director</td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Mark McKenna</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Apogee Therapeutics, Inc.</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Biotechnology</td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;">Chairman of the Board of Directors</td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Mirador Therapeutics, Inc.</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Biotechnology</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Chief Executive Officer and Chair of the Board of Directors</td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Spyre Therapeutics, Inc.</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Biotechnology</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Director</td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">New Amsterdam Pharma Company B.V.</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Biopharmaceutical</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Director</td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">McKenna Capital Partners</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Investment Firm</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Chief Investment Officer and Managing Director</td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Michael Henderson, M.D.</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Apogee Therapeutics, Inc.</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;">Biotechnology</td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;">Chief Executive Officer and Director</td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;">Spyre Therapeutics, Inc.</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;">Biotechnology</td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"> </td> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;">Director</td> </tr> </table> <div class="item-list-element-wrapper" style="margin-left:0.25in;tab-size:32px;display:flex;font-size:9.5pt;margin-top:9pt;justify-content:flex-start;font-family:'TradeGothic LT',sans-serif;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.166666666666667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">▪<div style="display:inline;">Our officers and directors are not required to, and will not, commit their full time to our affairs, which may result in a conflict of interest in allocating their time between our operations and our search for a business combination and their other businesses. We do not intend to have any full-time employees prior to the completion of our initial business combination. Each of our officers is engaged in several other business endeavors for which they may be entitled to substantial compensation, and our officers are not obligated to contribute any specific number of hours per week to our affairs.</div></div> <div class="item-list-element-wrapper" style="margin-left:0.25in;tab-size:32px;display:flex;font-size:9.5pt;margin-top:2pt;justify-content:flex-start;font-family:'TradeGothic LT',sans-serif;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.166666666666667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">▪<div style="display:inline;">Our initial shareholders purchased founder shares prior to the date of this prospectus and our sponsor will purchase private placement shares in a transaction that will close simultaneously with the closing of this offering. Our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have agreed to waive their redemption rights with respect to their founder shares, private placement shares and any public shares they may acquire during or after this offering in connection with the completion of our initial business combination. Additionally, our sponsor, officers and directors have agreed to waive their rights to liquidating distributions from the trust account with respect to their founder shares if we fail to complete our initial business combination within the prescribed time frame, although they will be entitled to liquidating distributions from assets outside the trust account. Furthermore, our sponsor, officers and directors have agreed not to transfer, assign or sell any of their founder shares and any Class A ordinary shares issuable upon conversion thereof until one year after the completion of our initial business combination or earlier if the last sale price of our Class A ordinary shares equals or exceeds $12.00 for any 20 trading days within any 30-trading day period commencing at least 180 days after the completion of our initial business combination. Because affiliates of TCGX and members of our board of directors will directly or indirectly own our securities following this offering, and accordingly, they may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction because of their financial interest in completing an initial business combination within the completion window.</div></div> <div class="item-list-element-wrapper" style="margin-left:0.25in;tab-size:32px;display:flex;font-size:9.5pt;margin-top:2pt;justify-content:flex-start;font-family:'TradeGothic LT',sans-serif;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.166666666666667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">▪<div style="display:inline;">In the event our sponsor or members of our management team provide loans to us to finance transaction costs and/or incur expenses on our behalf in connection with an initial business combination, such persons may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination as such loans may not be repaid and/or such expenses may not be reimbursed unless we consummate such business combination.</div></div>